← Back to Search

Radiopharmaceutical

Noninvasive Blood Flow Measurement for PET Brain Imaging (O-15 Water Trial)

Phase < 1
Waitlist Available
Research Sponsored by University of Alabama at Birmingham
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 years
Awards & highlights

O-15 Water Trial Summary

This trial is testing a new way to measure blood flow in the brain that is non-invasive and easy to use in a variety of settings.

Who is the study for?
This trial is for healthy men and women aged 19-60 with no neurological diseases. Ideal candidates should not have claustrophobia or metal implants, as MRI scans are part of the study.Check my eligibility
What is being tested?
The study tests a non-invasive method to measure brain blood flow using PET/MRI scans, comparing baseline imaging to images taken after taking Acetazolamide, which increases cerebral blood flow.See study design
What are the potential side effects?
Acetazolamide may cause side effects like tingling in fingers or toes, dizziness, nausea, blurred vision, and increased urination. The [O-15]Water used in PET scanning is generally considered safe with minimal risk.

O-15 Water Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Comparison of arterial sampling to non-invasive methods to measure regional cerebral blood flow using [O-15]water-PET/MRI

O-15 Water Trial Design

1Treatment groups
Experimental Treatment
Group I: [O-15]water PET/MRIExperimental Treatment2 Interventions
Volunteers will have two brain PET/MRI scans; first scan after injection of [O-15]water; second scan after injection of 1 gram of acetazolamide followed by injection of [O-15]water.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Acetazolamide
2011
Completed Phase 4
~2910

Find a Location

Who is running the clinical trial?

University of Alabama at BirminghamLead Sponsor
1,581 Previous Clinical Trials
2,278,029 Total Patients Enrolled

Media Library

[O-15]Water (Radiopharmaceutical) Clinical Trial Eligibility Overview. Trial Name: NCT03806751 — Phase < 1
Arterial Input Function PET Imaging Research Study Groups: [O-15]water PET/MRI
Arterial Input Function PET Imaging Clinical Trial 2023: [O-15]Water Highlights & Side Effects. Trial Name: NCT03806751 — Phase < 1
[O-15]Water (Radiopharmaceutical) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03806751 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What maladies is [O-15]Water employed to alleviate?

"O-15 Water is a medical intervention for salicylate poisoning and other issues, including edema, open angle glaucoma (OAG), and generalised glaucoma."

Answered by AI

Are individuals aged 35 and over able to participate in this research endeavor?

"Patients who meet the qualifications for this medical trial are aged 19 to 60 years. Separately, there is one study specifically designed for minors and 13 studies targeting seniors above 65."

Answered by AI

Is the study currently looking to enroll new participants?

"This medical investigation is not presently looking for participants. Initially published on February 1st 2024 and last edited March 29th 2022, there are currently one study recruiting patients with positron-emission tomography and 15 studies seeking volunteers willing to undergo [O-15]Water testing."

Answered by AI

What past investigations have made use of [O-15]Water?

"Currently, 15 trials are in progress concerning the properties of [O-15]Water with 4 reaching Phase 3. Detroit, Michigan is a hub for these studies yet 20 other medical facilities around the country have joined in on research as well."

Answered by AI

What eligibility criteria must a person satisfy to take part in this experiment?

"Patients must have undergone positron-emission tomography testing and be between 19 to 60 years of age in order to qualifiy for this trial. In total, the clinical trial is seeking 6 participants."

Answered by AI

What is the participant cap for this clinical investigation?

"Currently, this study is not open for recruitment. It was first posted on February 1st 2024 and last updated March 29th 2022. If you are searching for alternative trials, there are presently one trial utilizing positron-emission tomography PET imaging and fifteen studies focused around [O-15]Water that have opened their doors to participants."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
A Noninvasive Arterial Input Estimation Method for O-15 PET and Integrated PET/MR Scanning
Jonathan E McConathy 2025. "A Noninvasive Arterial Input Estimation Method for O-15 PET and Integrated PET/MR Scanning". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03806751.
~0 spots leftby Feb 2027
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top